AF
BOLT icon

Amalgamated Financial’s Bolt Biotherapeutics BOLT Stock Holding History

Amalgamated Financial’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$8K Buy
+138
New +$9.29K ﹤0.01% 2923

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ESCM
Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Amalgamated Financial's BOLT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Bolt Biotherapeutics (BOLT) in Q1 2022: 138 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2923 among its holdings.

65 funds tracked by Wall St. Rank hold BOLT as of Q1 2022.

  • Amalgamated Financial held 138 shares of Bolt Biotherapeutics worth $8K as of Q1 2022.
  • Bolt Biotherapeutics was a new Amalgamated Financial position in Q1 2022.
  • Bolt Biotherapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2923 holding.
  • 65 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.